AstraZeneca, a global, science-led biopharmaceutical company, announced that the company will present new data from its growing respiratory portfolio and pipeline at the annual meeting of the European Respiratory Society (ERS) International Congress, 3-7 September 2016 in London, UK.
The breadth and depth of science behind the portfolio and pipeline are reflected in the 38 accepted abstracts including nine oral presentations focused on unmet medical needs in asthma and chronic obstructive pulmonary disease (COPD). Highlights will include full phase III data for benralizumab, AstraZeneca’s first respiratory biologic, as well as new evidence for dual bronchodilation in COPD and for Symbicort in both COPD and asthma.
Sean Bohen, executive vice-president, global medicines development and chief medical officer at AstraZeneca, said: “The data presented at ERS reflect the breadth of our scientific research in chronic respiratory disease and our progress in delivering the next generation of respiratory therapies. We are particularly excited to share the full phase III data from the SIROCCO and CALIMA trials on benralizumab in severe asthma, where it is critical to improve outcomes for patients.”
Data from two pivotal phase III trials of benralizumab in severe asthma will be presented for the first time (abstracts #OA4832 and #OA1969).
New data will be presented on: A Duaklir (aclidinium/formoterol) study showing reduced deterioration in COPD compared to monotherapies and placebo (abstract #PA301); The benefit of Bevespi Aerosphere (glycopyrrolate and formoterol fumarate) over a 24-hour period versus tiotropium bromide inhalation spray and placebo (abstract #PA994); The effect of dual bronchodilation in all the Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages (abstracts #PA310 and #PA992).
Ten abstracts including new data on the benefit of Symbicort maintenance and reliever therapy in adolescents (abstract #PA4903) and real-world evidence of the disease burden in mild asthma (abstract #PA4590).